Eyeworld

SEP 2021

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1400530

Contents of this Issue

Navigation

Page 75 of 106

SEPTEMBER 2021 | EYEWORLD | 73 C Contact Ali: asim.ali@utoronto.ca Beckman: kenbeckman22@aol.com Holland: eholland@holprovision.com Corneal neurotization, he said, uses nerve grafts to connect nerves intact on the face to the eye or both eyes with neurotrophic disease. The nerves then grow down the grafts and into the cornea. He noted that this would not be a first- line treatment. The procedure can't be compared easily to other treatments because of how it works and how it fits in the treatment paradigm, he said. Oxervate would be the closest treatment, but there are no head-to-head comparisons, and Oxervate works differently, particularly in terms of healing the epithelium but not as much in improving sensation. Studies on neurotization have focused more on restoration of sensation. Neurotization takes a lot longer to be effective and works in a different way, he said. Corneal neurotization is more involved be- cause of the amount of surgery needed. He said there are a number of techniques/modifications that are being used successfully as well. Dr. Holland said he has had good experi- ence so far using Oxervate. It works in some pa- tients extremely well and in others not as well, he said. "I see it work well when the NK is not extremely longstanding and the patients are a bit younger." Severe NK in older patients doesn't tend to respond as well, he said. Corneal neurotization Corneal neurotization is a newer treatment approach. Both Dr. Beckman and Dr. Holland said they are not currently performing this procedure. Dr. Beckman noted that he works with another specialist who is performing the procedure and said it seems promising. Dr. Ali was involved in pioneering this approach. He's had about 6 years of experience, having been involved in publications 1,2 that described the technique. He uses nerve grafts but noted that allografts and nerve transfers can also be used in this process. Stage 2 shows an epi defect with no thinning. Stage 3 shows an epi defect with stromal thinning. Source (all): Kenneth Beckman, MD

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SEP 2021